Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene (This gene does not contain this module)
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target< (This gene does not contain this module)

Gene: HLA-C

Summary for HLA-C

Gene information	Gene symbol	HLA-C
	Ensembl ID	ENSG00000206435
	Entrez ID	3107
	Gene name	major histocompatibility complex, class I, C
	Synonyms	D6S204\|HLA-JY3\|PSORS1
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: HLA-C

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE140440	DU145 and PC cell lines	Cell line	Prostate cancer	Prostate cancer	Chemotherapy	docetaxel	NA	Malignant cells	0.918501	2.64e-10
GSE186960	Panc1 cell line	Cell line	Pancreatic cancer	Pancreatic ductal adenocarcinoma (PDAC)	Chemotherapy	gemcitabine	NA	Malignant cells	-0.49052	0.00e+00
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	0.624911	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.636114	1.32e-24
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.581333	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.598836	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.480185	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	0.314817	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.256508	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.699599	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	0.406272	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	B cells	0.688737	3.12e-41
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	NK cells	0.72308	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	CD8+ T cells	0.385139	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.597245	2.67e-06
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Plasma cells	0.480022	5.09e-18
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	pDCs	0.892099	4.48e-04
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	Mono/Macro	0.752465	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.589581	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	cDCs	-0.938973	6.18e-12
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	NK cells	-0.471588	1.31e-22
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.505513	0.00e+00
GSE153697	patients	Bone marrow aspirate	Acute lymphoblastic leukemia	Relapsed B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	anti-CD19 CAR-T	NA	Malignant cells	-0.383962	6.77e-36
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.560738	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.772753	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	0.349057	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.279695	2.04e-05
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.587483	1.69e-10
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	0.527597	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	pDCs	0.688571	5.02e-05
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD4+ T cells	0.777334	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	B cells	0.794451	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Plasma cells	0.347528	1.51e-03
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	Mono/Macro	0.820063	1.48e-27
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	NK cells	0.60741	2.81e-25
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	post	CD8+ T cells	0.426794	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	NK cells	0.77643	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD4+ T cells	0.497164	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	B cells	0.294392	1.48e-20
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	CD8+ T cells	0.323008	0.00e+00
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mast cells	-1.57736	8.19e-08
GSE169246_PacAteTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	Mono/Macro	-0.373443	5.35e-33
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	Progenitors	0.597232	1.02e-04
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	-0.437528	5.37e-12
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD8+ T cells	0.541922	1.35e-15
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Erythrocytes	-0.31603	5.41e-18
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD4+ T cells	-0.566619	0.00e+00
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	-0.368741	0.00e+00
GSE212217	patients	Peripheral blood mononuclear cells	Endometrial cancer	Epigenetic MMRd endometrial carcinoma	Immunotherapy	pembrolizumab	post	Plasma cells	0.532811	6.93e-04
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	post	CD8+ T cells	-0.360745	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.412206	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	0.394518	2.76e-19
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	0.751096	1.98e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mast cells	1.52012	8.00e-07
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	0.354908	7.17e-08
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	0.257606	3.46e-21
GSE207422_Sin	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	sintilimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	0.397808	9.28e-29
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD8+ T cells	0.466056	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	CD4+ T cells	0.498443	0.00e+00
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	post	Mono/Macro	0.333611	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD4+ T cells	-0.469356	2.04e-34
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	B cells	-1.24656	6.57e-22
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Plasma cells	-0.288525	8.02e-03
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	CD8+ T cells	-0.414261	0.00e+00
GSE207422_Tor	patients	Tumor tissue	Lung cancer	EGFR/ALK mutation negative non-small cell lung cancer (NSCLC)	Immunotherapy	toripalimab + carboplatin + (docetaxel or pemetrexed or emcitabine)	post	Mono/Macro	-0.323042	6.21e-05
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	B cells	0.396296	1.27e-13
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	cDCs	0.582796	5.13e-05
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	Mono/Macro	0.288056	0.00e+00
GSE189460	patients	Bone marrow aspirate	Multiple myeloma	Multiple myeloma (MM)	Targeted therapy	bortezomib + melphalan + prednisolone	pre	pDCs	0.778097	7.75e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	NK cells	0.384103	2.04e-33
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	CD8+ T cells	0.316905	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	post	Malignant cells	-1.29569	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	NK cells	0.275347	2.66e-03
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	Malignant cells	-0.689302	0.00e+00
GSE161801_PI	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	carfilzomib + dexamethasone	pre	CD8+ T cells	0.396303	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	0.641598	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	cDCs	-0.358281	2.08e-16
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Malignant cells	-0.304611	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD8+ T cells	-0.509265	1.55e-17
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	NK cells	-0.31671	3.05e-05
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Malignant cells	-0.45984	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	pre	Erythrocytes	-0.950535	6.38e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	-0.469871	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	-0.478296	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	-0.45951	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	-0.896103	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Erythrocytes	-0.676726	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Malignant cells	-0.705464	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD4+ T cells	-0.407821	4.94e-17
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.813055	9.75e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.253231	3.94e-07
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	Erythrocytes	-1.29243	0.00e+00
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	CD8+ T cells	0.336377	8.06e-11
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.685235	0.00e+00
GSE131984_JQ1	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1	NA	Malignant cells	-0.429158	2.59e-35
GSE131984_JQ1Pac	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + paclitaxel	NA	Malignant cells	-0.252671	3.30e-07
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	-0.515467	4.64e-42
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	NK cells	-0.428343	2.84e-40
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	CD4+ T cells	-0.598562	1.43e-23
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	B cells	-0.787281	1.70e-27
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Mono/Macro	-0.280495	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD4+ T cells	-0.49985	1.51e-26
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	NK cells	-0.754195	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	CD8+ T cells	-0.516833	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	B cells	-0.332006	1.78e-28
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	0.716857	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	cDCs	-0.390325	1.05e-04

Top

Expression of HLA-C in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to HLA-C

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Gene symbol	Cell type with DEG	Interaction ID	Interacting pair	Gene A	Gene B	Integrin	Interacting cell type1	Interacting cell type2	Dataset	Timepoint	Condition
HLA-C	Malignant cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	Malignant cells	NK cells	GSE153697	NA	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE161801_IMiD	post	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Malignant cells	NK cells	GSE161801_IMiD	post	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE161801_IMiD	post	resistant
HLA-C	Malignant cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Malignant cells	NK cells	GSE161801_IMiD	pre	resistant
HLA-C	CD8+ T cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE161801_IMiD	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE161801_IMiD	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Malignant cells	NK cells	GSE161801_IMiD	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE161801_IMiD	pre	resistant
HLA-C	CD8+ T cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	NK cells	GSE161801_PI	post	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	NK cells	GSE161801_PI	post	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	NK cells	NK cells	GSE161801_PI	post	resistant
HLA-C	CD8+ T cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	CD8+ T cells	GSE161801_PI	pre	resistant
HLA-C	CD8+ T cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE161801_PI	pre	resistant
HLA-C	CD8+ T cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	NK cells	GSE161801_PI	pre	resistant
HLA-C	CD8+ T cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	NK cells	CD8+ T cells	GSE161801_PI	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE161801_PI	pre	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	NK cells	GSE161801_PI	pre	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	NK cells	CD8+ T cells	GSE161801_PI	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE161801_PI	pre	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	NK cells	NK cells	GSE161801_PI	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	NK cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	NK cells	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	CD8+ T cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	CD8+ T cells	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	Mono/Macro	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	Mono/Macro	CPI-SS0ABD11350	HLA-C_KIR2DL1	HLA-C	KIR2DL1	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	post	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	post	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	post	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE169246_PacAteBlood	post	sensitive
HLA-C	CD8+ T cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	post	sensitive
HLA-C	Mono/Macro	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	post	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE169246_PacAteBlood	pre	resistant
HLA-C	Mono/Macro	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacAteBlood	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacAteBlood	pre	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE169246_PacAteBlood	pre	sensitive
HLA-C	CD8+ T cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacBlood	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacBlood	pre	resistant
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE169246_PacBlood	pre	resistant
HLA-C	CD8+ T cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacBlood	pre	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD4+ T cells	NK cells	GSE169246_PacBlood	pre	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	CD8+ T cells	NK cells	GSE169246_PacBlood	pre	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	Mono/Macro	NK cells	GSE169246_PacBlood	pre	sensitive
HLA-C	NK cells	CPI-SS0917CBD53	HLA-C_KIR2DL3	HLA-C	KIR2DL3	False	NK cells	NK cells	GSE169246_PacBlood	pre	sensitive

Page: 1 2

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating HLA-C

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
HLA-C	hsa-miR-4524a-3p	90.2794	NM_002117
HLA-C	hsa-miR-9500	89.8476	NM_002117
HLA-C	hsa-miR-518c-5p	83.8663	NM_002117
HLA-C	hsa-miR-6822-5p	83.3544	NM_002117

Page: 1

Top

Motifs and transcription factors (TFs) regulating HLA-C

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."